«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年03期

页码:

368-372

栏目:

论著

出版日期:

2024-06-25

文章信息/Info

Title:

Influence of nintedanib on pulmonary function, pulmonary fibrosis degree and serum PDGF, PGE2 and TGF-β1 levels in patients with idiopathic pulmonary fibrosis

作者:

周 璇; 谢 莉; 邹 娟

610000 成都,四川大学华西医院呼吸综合科

Author(s):

Zhou Xuan;  Xie Li;  Zou Juan.

General Respiratory Department, West China Hospital, Sichuan University, Chengdu, 610000, China

关键词:

特发性肺纤维化;  肺功能;  尼达尼布;  血清前列腺素E2;  转化生长因子-β1

Keywords:

Nintedanib;  Idiopathic pulmonary fibrosis;  Pulmonary function;  Pulmonary fibrosis degree;  Serum prostaglandin E2;  Transforming growth factor -β1

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2024.03.005

摘要:

目的 分析尼达尼布对特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)患者肺功能、肺纤维化程度及血小板衍生细胞因子(platelet-derived growth factor, PDGF)、血清前列腺素E2(prostaglandin E2, PGE2)、血清转化生长因子-β1(transforming growth factor-β1, TGF-β1)水平的影响。方法 选择2019年3月至2023年3月我院收治的IPF患者152例为对象,给予常规+吡非尼酮治疗65例为对照组,常规治疗基础上加用尼达尼布治疗87例为观察组。比较两组治疗后临床疗效和不良反应,比较两组治疗前后的肺功能、血管内皮功能、肺纤维化程度、促纤维化相关因子水平。结果 观察组治疗后有效85例(97.70%)高于对照组58例(89.23%)(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。两组治疗后肺功能指标、内皮源性一氧化氮(nitric oxide, NO)较治疗前提高,观察组FEV₁[(2.05±0.23)vs.(1.88±0.27)]L,FVC[(2.14±0.21)vs.(1.93±0.27)]L,DL_CO[(16.19±1.51)vs.(14.84±1.73)]ml/(min?mmHg),NO[(825.10±98.37)vs.(746.01±77.78)]nmol/L高于对照组(P<0.05); 两组肺纤维化程度、血管内皮素-1(endothelin-1, ET-1)、促纤维化相关因子水平较治疗前降低,观察组Ⅳ C[(89.25±12.23)vs.(95.58±14.54)]ng/ml,HA[(185.44±23.01)vs.(197.23±27.17)]ng/ml,胸部CT影像学评分[(1.56±0.18)vs.(1.70±0.20)] 分,ET-1[(57.78±10.05)vs.(70.14±10.53)]ng/L,PDGF[(136.85±61.07)vs.(217.47±67.12)]ng/L、PGE2[(258.57±50.28)vs.(329.28±71.43)]ng/L、TGF-β1[(159.41±115.91)vs.(236.92±137.89)]ng/L低于对照组(P<0.05)。结论 尼达尼布能有效治疗IPF,改善肺功能、血管内皮功能指标、肺纤维化程度,降低促纤维化相关因子水平具有意义。

Abstract:

Objective To analyze the influence of nintedanib on pulmonary function, pulmonary fibrosis degree, serum platelet-derived growth factor(PDGF), prostaglandin E2(PGE2), and serum transforming growth factor-β1(TGF-β1)in patients with idiopathic pulmonary fibrosis(IPF). Methods 152 patients with IPF in the hospital were selected as the subjects from March 2019 to March 2023. 65 patients who were treated with routine treatment + pirfenidone were included in control group, and 87 patients who received nintedanib based on routine treatment were enrolled as observation group. The clinical efficacy and adverse reactions after treatment and pulmonary function indicators, vascular endothelial function indicators, pulmonary fibrosis degree and pro-fibrosis-related factors before and after treatment were compared between both groups. Results After treatment, the total effective rate in observation group was higher than that in control group [85 cases(97.7%)vs. 58 cases(89.2%)](P<0.05). There were no statistical differences in the adverse reactions between groups(P>0.05). The pulmonary function indicators and endothelial nitric oxide(NO)in both groups were enhanced after treatment than those before treatment, and FEV₁[(2.05±0.23)vs.(1.88±0.27)]L, FVC[(2.14±0.21)vs.(1.93±0.27)]L, DL_CO[(16.19±1.51)vs.(14.84±1.73)]ml/min?mmHg and NO[(825.10±98.37)vs.(746.01±77.78)]nmol/L were higher in observation group than those in control group(P<0.05). The pulmonary fibrosis degree, endothelin-1(ET-1)and pro-fibrosis-related factors were reduced in the two groups compared with those before treatment, and Ⅳ C [(89.25±12.23)vs.(95.58±14.54)]ng/ml, HA[(185.44±23.01)vs.(197.23±27.17)]ng/ml, chest CT imaging score[(1.56±0.18)vs.(1.70±0.20)] points, ET-1[(57.78±10.05)vs.(70.14±10.53)]ng/L, PDGF[(136.85±61.07)vs.(217.47±67.12)] ng/L, PGE2[(258.57±50.28)vs.(329.28±71.43)]ng/L and TGF-β1 [(159.41±115.91)vs.(236.92±137.89)]ng/L in observation group were lower compared to control group(P<0.05). Conclusion Nintedanib can effectively treat IPF, improve pulmonary function, vascular endothelial function indicators and pulmonary fibrosis degree, and reduce the levels of pro-fibrosis-related factors.

参考文献/References:

1 胡 琴, 刘田田, 许朋俐, 等. 基于线粒体自噬的特发性肺纤维化发病机制和药物干预的探讨[J]. 生理科学进展, 2023, 54(1): 52-56.
2 于 娜, 周家为, 李 霞, 等. 成人特发性肺纤维化(更新)和进行性肺纤维化临床实践指南(2022版)解读[J]. 中国现代医学杂志, 2023, 33(14): 1-8.
3 孙 晖, 任 莉, 胡静星, 等. Ⅳ型胶原蛋白、Ⅲ型前胶原氨基端肽与老年特发性肺纤维化病人肺功能和急性加重的相关性[J]. 实用老年医学, 2023, 37(9): 929-933.
4 Strykowski R, Adegunsoye A. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis[J]. Immunol Allergy Clin North Am, 2023, 43(2): 209-228.
5 魏会强, 侯彦琨, 郝秀玲, 等. Bcl-2-like 11基因多态性与肺间质纤维化肺功能和肺部感染的关联[J]. 中华医院感染学杂志, 2023, 33(6): 826-830.
6 Glass DS, Grossfeld D, Renna HA, et al. Idiopathic pulmonary fibrosis: Current and future treatment[J]. Clin Respir J, 2022, 16(2): 84-96.
7 Ghazipura M, Mammen MJ, Bissell BD, et al. Pirfenidone in progressive pulmonary fibrosis: A systematic review and Meta-analysis[J]. Ann Am Thorac Soc, 2022, 19(6): 1030-1039.
8 王 帅, 王亚文, 邹永祎, 等. 尼达尼布治疗特发性肺纤维化92例对肺功能和肺纤维化指标的影响及不良反应分析[J]. 安徽医药, 2023, 27(4): 826-829.
9 中华医学会呼吸病学分会间质性肺疾病学组. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
10 Tabatabaei MS, Ahmed M. Enzyme-linked immunosorbent assay(ELISA)[J]. Methods Mol Biol, 2022, 2508: 115-134.
11 中华医学会病理学分会胸部疾病学组. 中国特发性肺纤维化临床-影像-病理诊断规范[J]. 中华病理学杂志, 2018, 47(2): 81-86.
12 孙宇新, 黄 慧. 尼达尼布联合吡非尼酮治疗特发性肺纤维化的INJOURNEY研究[J]. 中华结核和呼吸杂志, 2018, 41(5): 339.
13 Munchel JK, Shea BS. Diagnosis and management of idiopathic pulmonary fibrosis[J]. R I Med J(2013), 2021, 104(7): 26-29.
14 许 娟, 张党锋. 尼达尼布对肺纤维化小鼠肺功能及内质网应激反应的影响[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(5): 673-675.
15 Pan L, Cheng Y, Yang W, et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K/Akt/mTOR pathway in mice[J]. Inflammation, 2023, 46(4): 1531-1542.
16 Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial[J]. Eur Respir J, 2022, 60(6): 2200380.
17 Jamadar A, Suma SM, Mathew S, et al. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease[J]. Cell Death Dis, 2021, 12(10): 947.
18 Wijsenbeek M, Swigris JJ, Inoue Y, et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis[J]. Eur Respir J, 2024, 63(2): 2300752.
19 丁 旻, 李佳旻, 洪群英, 等. 尼达尼布治疗特发性肺纤维化的长期疗效及安全性:单中心参与INPULSIS及INPULSIS ON的系列病例分析[J]. 复旦学报(医学版), 2022, 49(3): 395-401.
20 Pulito-Cueto V, Genre F, López-Mejías R, et al. Endothelin-1 as a Biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases[J]. Int J Mol Sci, 2023, 24(2): 1275.
21 李怡华, 叶 俏. 抗肺纤维化药物尼达尼布和吡非尼酮临床试验进展[J]. 中华劳动卫生职业病杂志, 2020, 38(1): 62-65.
22 李海娜, 刘 畅, 王金柱, 等. 尼达尼布联合参附注射液对百草枯中毒大鼠肺损伤的保护作用[J]. 中华劳动卫生职业病杂志, 2023, 41(2): 81-86.
23 Li X, Xi B, Miao Y, et al. Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling[J]. Int Immunopharmacol, 2021, 100: 108129.
24 Liu F, Yu C, Qin H, et al. Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial-to-mesenchymal transition, inflammation and angiogenesis[J]. J Cell Mol Med, 2021, 25(13): 6103-6114.
25 张 秀, 杨三春. 尼达尼布对肺纤维化患者内皮素-1、血管紧张素的影响[J]. 临床输血与检验, 2020, 22(1): 68-71.
26 Chen R, Dai J. Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy[J]. J Mol Med(Berl), 2023, 101(8): 905-915.
27 邓 泽, 戢新平. 吡非尼酮联合尼达尼布治疗特发性肺纤维化患者的临床研究[J]. 中国临床药理学杂志, 2022, 38(11): 1174-1176, 1194.
28 黄晓娜, 李 龙, 赵 华. 前列腺素E 2在特发性肺纤维化中的作用[J]. 国际呼吸杂志, 2022, 42(8): 623-629.
29 李佳怡, 王亚菲, 郝月琴, 等. CXCL14、TGF-β1和CTGF水平与特发性肺纤维化的关系[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 222-224.

备注/Memo

备注/Memo:

基金项目: 四川省科技计划项目(2018SZ0240)
通信作者: 周 璇, Email: Zx15828555501@163.com

常用功能

更新日期/Last Update: 2024-06-25